Farrukh T Awan, Ran Liu, Hsin-Hui Huang, Matthew Bye, Kwang Woo Ahn, Gabriel Krigsfeld, Anat Raz, Heather Wolfe, Mehdi Hamadani
After adjusting for confounders, the ibrutinib cohort had significantly better overall survival (adjusted hazard ratio, 0.39; 95% confidence interval, 0.23-0.68; p = 0.0008) than the allogeneic haematopoietic stem cell transplantation (alloHSCT) cohort. Our large, retrospective analysis suggests that ibrutinib treatment may offer improved overall survival and progression-free survival compared to alloHSCT in patients with relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma.